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driving innovation: 
How stronger laws Pull safer cHemicals into tHe market
By Baskut Tuncak*
InTroducTIon
No one can deny that many of the features of modern life owe much to the ingenuity of the chemical industry. New chemicals, new applications for existing chemi-
cals, and new chemical processes enabled a host of innovations 
across a range of industries and led to the growth of the chemi-
cal industry over the past several decades. Since the 1970s, the 
output of the chemical industry has grown from approximately 
US$ 1 trillion adjusted for inflation to US$ 4.12 trillion in 2010, 
with estimates for 2020 approaching US$ 6.5 trillion.1 As the 
scale of the chemical industry has grown so too has evidence 
of the adverse effects of chemicals on human health and the 
environment. 
Innovation is especially relevant today as the establishment 
of the chemical industry, from manufacturers to formulators, 
face increasing pressure from two fronts.2 First, after overtaking 
traditional leaders such as the United States and Western Europe 
in bulk chemical manufacturing, emerging economies are posi-
tioning themselves to become leaders in chemical innovation.3 
Simultaneously, the chemical industry is also facing increasing 
pressure from downstream users, retailers, and consumers to 
provide safer products through the development and use of safer 
chemicals. 
A common refrain by the regulated (or soon-to-be regu-
lated) industry is that stricter laws over hazardous chemicals will 
impede innovation, reducing economic growth, competitiveness, 
and employment. We define “laws” to include legislation, regu-
lation, directives, decisions, rules, and other forms of enforce-
able standards at the sub-national, national, regional, and global 
level. Current laws in the European Union and United States 
designed to protect people and the environment from hazardous 
chemicals aim to enhance innovation.4 However, both European 
and American laws have shortcomings in terms of their ability 
to prevent harm, the costs of which are borne by individuals and 
society-at-large, and to encourage the entry of safer alternatives. 
Can stricter laws over hazardous chemicals drive innovation? 
Can it drive innovation while also sending it in a safer direction? 
Reviewing recent measures to reduce the risk of harm from 
additives to plastics (phthalates), toxic flame retardant chemi-
cals (“PBDEs”), refrigerants (“CFCs”), and pesticides (methyl 
bromide), this article focuses on the features of policies that 
stimulated innovation and the factors that led to satisfactory or 
unsatisfactory outcomes. Examining patents as an indication of 
rates of invention, this article explores the types of inventions 
that downstream users and consumers in the market subse-
quently adopted. 
This article presents findings regarding the efficacy of past 
measures and the potential of stricter laws to accelerate innova-
tion toward safer chemicals. First, the article presents findings 
on the human health effects of hazardous chemicals, illustrating 
the pressing need for innovation around safer chemicals. The 
next section discusses the rate at which alternatives are invented 
in response to the prospect of stricter laws. Then, the article 
examines the types of inventions adopted by downstream users 
after regulators take measures, exploring why the transition may 
or may not have been to safer alternatives. Fourth, the article 
looks at how the law can help safer alternatives overcome barri-
ers to entry, enabling early adopters to gain competitive advan-
tage through innovation and an opportunity to optimize their 
return on new investments. The final section presents findings 
on how stricter laws direct resources to the innovation of safer 
alternatives. 
human healTh eFFecTs lInked To  
hazardous chemIcals
As the scale of the chemical industry has grown since the 
1970s so too has evidence of the adverse effects of chemicals on 
human health and the environment. According to Eurostat, the 
share of toxic chemicals in the total production of chemicals is at 
62%.5 Analyses of household cleaners, plastic products (includ-
ing toys), clothing, and other everyday products show that many 
such products can contain over seventy chemicals considered of 
very high concern.6 Recent biomonitoring studies confirm the 
migration of hundreds of hazardous chemicals from everyday 
products into people, either directly, or through food, water, air, 
household dust, and other sources.7 Of significant concern is the 
exposure of children to a potent cocktail of hazardous chemicals 
during critical windows of development. These exposures occur 
through their mother’s womb and breast milk, as well as from 
broader environmental sources mentioned above. The effects of 
exposure to these chemicals at an early age often do not manifest 
for many years or even decades.
There is an increasing incidence of many diseases around 
the world, including many that were much less prevalent in chil-
dren in decades past. These trends include: 
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• A 24% increase of childhood cancers such as leukemia and 
brain cancer since 1975 and a forty percent increase in the 
incidence of breast cancer between 1973 and 1998;8 
• Asthma, which approximately doubled in prevalence 
between 1980 and 1995, continues to rise;9
• Forty percent more women reported difficulty conceiving 
and maintaining a pregnancy from 1982 to 2002. From 1982 
to 1995, the incidence of reported difficulty almost doubled 
in younger women, ages 18–25;10
• Sharp increases in male genital malformations;11
• Learning and developmental disabilities, including autism 
and attention deficit hyperactivity disorder, affect nearly one 
in six U.S. children, as of 2008;12 
• Doubling of the rate of diabetes in the United States and 
England, with increasing frequency among young popula-
tions;13 and
• Dramatic rise in the prevalence of obesity among both older 
and younger populations, and both wealthy, industrialized 
countries as well as poorer developing countries.14 
There is growing consensus about the role of chemicals in 
the increasing incidence of many disorders around the world. 
Among many factors, there is increasing evidence that exposure 
to endocrine disrupting chemicals (“EDCs”) at an early age is 
linked to many of these disorders.15 
An EDC is a chemical, or mixture of chemicals, that inter-
feres with any aspect of hormone action.16 Suspected EDCs are 
commonly found in people, wildlife, and the environment. Over 
800 chemicals have been identified as having endocrine disrupt-
ing properties.17 All of the twenty-two chemicals listed under 
the Stockholm Convention, a global treaty that restricts or bans 
some of the most hazardous chemicals used around the world, 
have endocrine disrupting properties.18 
The adverse effects that are increasingly linked to expo-
sure to chemicals with endocrine disrupting properties include: 
effects on reproduction, such as infertility and reduced sperm 
count and viability; breast, mammary, testicular, and prostate 
cancers; type 2 diabetes, obesity, and heart disease; neurobehav-
ioral outcomes; and thyroid and immune system dysfunction.19
There are several key features of endocrine disrupting 
chemicals that make exposure to any dose of an EDC unsafe, 
including effects at low doses,20 cumulative effects,21 permanent 
adverse effects during critical developmental windows,22 effects 
on future generations,23 and ubiquity in the environment.24
sTrIcTer chemIcal laws spark The  
InvenTIon oF alTernaTIves
A common argument against the prospect of stricter rules 
to protect people and the environment from hazardous chemi-
cals is that there is not a viable alternative to the chemical.25 
This argument might be made for technical reasons, such as the 
“performance” of the chemical relative to alternatives, or the 
lack of manufacturing capacity for alternatives. It can also be 
made for economic reasons, where an alternative is argued to be 
prohibitively expensive. Restricting or banning the chemical of 
concern would, the argument goes, reduce the competitiveness 
of a product or may even result in the unavailability of a product 
or process from the market altogether. The argument is essen-
tially a threat of lost profits, jobs, and competitiveness at the 
global level.26
These arguments, however, ignore our ability to invent bet-
ter solutions and re-design the way people interact with their 
environment. This section reviews chemicals of concern, ranging 
from industrial chemicals in consumer products to pesticides, 
under national, regional, and global environmental laws. Review 
was limited to chemicals that have sufficient information about 
their hazardous properties and are subject to significant scrutiny 
in more than one region of the world. In each case, the prospect 
of stricter rules for certain chemicals sparked the invention and 
development of alternatives, including incremental improve-
ments in the performance of pre-existing alternatives.27 Stricter 
laws are defined as those that: (a) require a significant reduc-
tion in exposure to hazardous chemicals; (b) require compli-
ance through the use of comparatively costly technology; or (c) 
require significant technological change.28 Below are findings 
for two chemicals or classes of chemicals of concern that also 
clearly illustrate this trend: phthalates, a widely used endocrine 
disrupting chemical; and chlorofluorocarbons, an ozone deplet-
ing substance. 
PHtHalates
Phthalates are a class of chemicals used as plasticizers to 
soften certain plastics. Ninety percent of phthalate production, 
estimated to be in the millions of tons per year, is used to plas-
ticize polyvinyl chloride (“PVC”).29 As a plasticizer, phthalates 
are not bound to the plastic polymer, so they leach out of prod-
ucts, resulting in exposure for people and wildlife and contami-
nating homes and the environment.30 Phthalates are also used as 
solvents in many cosmetics that are applied directly to the skin, 
including perfumes, lotions, soaps, shampoos, deodorants, and 
hair care products.
Certain phthalates are widely recognized as EDCs. Some 
disturbing genital deformations associated with phthalate expo-
sure in animals have earned the title of “phthalate syndrome.”31 
Other potential adverse effects include cancer, obesity, diabetes, 
and attention deficit hyperactivity disorder.32 Like other EDCs, 
these effects are believed to correlate with exposure during 
critical windows of development. Recent studies have detected 
phthalate metabolites in a high percentage of people tested. 
Some cases found phthalate metabolites in all urine samples 
analyzed.33 
Beginning in 1998, following European leadership, countries 
around the world took measures to protect human health from 
certain hazardous phthalates. In addition to the Member States 
of the European Union (“EU”), Canada, Japan, Iceland, Mexico, 
Norway, Argentina, Tunisia, and the United States are among the 
many countries that took measures to ban or restrict the use of 
certain phthalates. The EU added four of these phthalates (BBP, 
DEHP, DBP, and DIBP) to the EU’s REACH Candidate List, and 
subsequently the REACH Authorization List.34 Through their 
inclusion on the Authorization List, all uses of these phthalates 
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in the EU are required to cease by February 21, 2015, unless 
for a specifically authorized use.35 Certain Member States of the 
EU continue to pursue more stringent domestic measures than 
measures at the regional level.36 
These measures may have sparked the invention of alter-
natives to certain uses of phthalates. Publicly available patent 
records illustrate a surge of inventions (measured by “patent 
families”) to eliminate exposure to phthalates. There is a notice-
able acceleration in the filing of patents, and thus the pace of 
invention, beginning around 1999, following the initial EU mea-
sures, and accelerating again in 2006, around the adoption of 
REACH. These time points correlate with years in which Europe 
led the world in adopting measures to reduce the use of certain 
phthalates. 
Figure 1. Spike in Patented Inventions Free of Hazardous 
Phthalates.
Considering the varying degree of research and develop-
ment required before filing a patent, inventors likely foresaw the 
enactment of stricter laws and began research necessary for the 
patent application beforehand, filing when new laws appeared 
imminent to maximize their time-period of exclusivity under the 
patent.37 Because these events took place long before compliance 
deadlines, companies were afforded the necessary lead-time to 
develop and possibly patent their technological inventions. For 
example, the EU’s temporary directive in 1999 was proceeded 
by a Recommendation by the European Commission in July 
1998, which itself was preceded by an opinion of the European 
Commission’s Scientific Committee on Toxicity, Ecotoxicity, 
and the Environment in April 1998.38 
The correlation of increased invention in response to the 
prospect of stricter laws is consistent with other lessons of the 
past. For example, investigations of regulatory events surround-
ing lead, mercury, polychlorinated biphenyls (“PCBs”), and 
vinyl chloride also confirm that informal regulatory procedures 
before rulemaking began drove companies to develop their tech-
nological responses.39 
Yet it was not until significantly strict measures appeared 
likely (inclusion in the Authorization List under the EU’s 
“REACH” Regulation) that major chemical manufacturers and 
others significantly increased their patenting of alternatives. 
Nearly one-half of the patented inventions claiming an alterna-
tive to phthalates reference the health and environmental con-
cerns surrounding this class of chemicals. 
Figure 2. Stricter Laws Trigger Innovation by Major Chemical 
Manufacturers. 
Following Evaluation of the information provided, an EU 
Member State or the European Chemical Agency (“ECHA”) 
may propose to identify a chemical as a Substance of Very High 
Concern (“SVHCs”)40 and place it on the REACH “Candidate 
List.” Subsequently, ECHA can recommend a chemical on 
the Candidate List for Authorization. If approved by the 
European Commission, the chemical is placed on the REACH 
Authorization List, in which case companies must request autho-
rization for specified uses after a “Sunset Date.” 
According to the European Commission’s interim evalua-
tion of the impact of REACH on innovation in Europe (“REACH 
Innovation Report”), “the Candidate List is a, if not the, major 
driver for change at present.”41 As more information about the 
intrinsic hazards of chemicals within the scope of REACH 
becomes available, the Candidate List stands to continue to 
drive innovation in the chemical industry.42 With broad criteria 
for identifying endocrine disrupting chemicals and information 
about endocrine disrupting properties of chemicals, it stands to 
reason that the Candidate List will further drive innovation.
cfcs
Chlorofluorocarbons (“CFCs”) displaced ammonia, sulfur 
dioxide, carbon dioxide, and other “natural” refrigerants in 
the 1930s. Unlike these refrigerants, countries adopted CFCs 
because they offered a safer alternative in terms of their toxicity, 
flammability, and/or energy efficiency.43 Unfortunately, it was 
not until many decades later that these chemicals were widely 
acknowledged to be ozone depleting substances.44 Other uses 
for CFCs included foam production (e.g. Styrofoam™), aerosol 
products, and solvents for cleaning products with delicate com-
ponents such as electronics. 
Chemical companies were alert to the human health and 
environmental consequences of CFC emissions as early as 1972. 
Following a 1972 conference, DuPont and other CFC manu-
facturers formed a consortium coordinated by what is now the 
American Chemistry Council (“ACC”), a U.S. trade association 
for chemical manufacturers.45 When ozone depletion resulting 
from CFC emissions began to gain substantial mainstream atten-
tion in 1974, members of the consortium defended the continued 
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use of CFCs, and called for additional scientific evidence, insist-
ing their chemicals were safe until proven otherwise. They also 
argued that health and wealth would decline in a world without 
CFC products.46
Simultaneously, research and development into alternatives 
was well underway, with several alternatives identified. During 
debate over stricter measures on CFCs and other ozone depleting 
substances, representatives of DuPont and other CFC manufac-
turers stated that they had identified technically viable alterna-
tives to CFCs between 1975 and 1980 but could not introduce 
these alternatives because, by their estimates, the alternatives 
would not be economically viable.47 Later, these manufacturers 
acknowledged that it was the lack of legally-enforceable stan-
dards that prevented the entry of safer alternatives.48
The United States, Canada, Sweden, and Norway announced 
plans to ban non-essential aerosol products in 1976, aided in part 
by slumping sales of CFC-containing products due to consumer 
concern. These laws at the national level spurred changes in the 
industry, most notably in the United States. Changes in the U.S. 
industry in turn positioned the United States well to push more 
actively for international laws over ozone depleting substances, 
given its own competitive advantage.49 
In 1987, countries around the world agreed on a timeline 
for the global phase out of CFCs under the Montreal Protocol.50 
A patent search by the World Intellectual Property Organization 
showed that various chemical manufacturers and other diversi-
fied businesses in both Japan and the United States patented a 
variety of processes, including the process for the manufacture 
of one of the most widely used alternatives to CFCs, hydrofluo-
rocarbon (HFC)-134a, in 1987 and 1988.51
Thus, the prospect of stricter laws at the national and global 
level spurred inventors to research alternatives to CFCs and 
hydrochlorofluorocarbons (“HCFCs”), leading to the develop-
ment of both HFCs and inventions for the safer use of “natural” 
refrigerants (used in the 1930s before CFCs) as alternatives 
to CFC refrigerants.54 HFCs prevailed over ammonia, carbon 
dioxide (“CO2”), and other “natural” refrigerants due to the 
cost advantages. However, while HFCs are not ozone depleting 
substances, they are potent greenhouse gasses. Aided by stricter 
rules in Europe that phased out HFCs in new cars after 2011 
and public campaigns to use hydrocarbons in domestic refrigera-
tors, considerable research and development continued around 
the use of natural refrigerants.55 Incremental inventions enabled 
these “natural” refrigerants to overcome properties deemed 
undesirable almost a century ago (see Table 1). With the contin-
ued development of natural refrigerants, hydrocarbon domestic 
refrigerators are now economically viable and commonly avail-
able in Europe and Asia, with both environmentalists and manu-
facturers alike advocating for the United States to adopt them as 
well.56 In addition, suppliers of equipment using ammonia rather 
than HCFCs recaptured market share in cold storage and food 
freezing.57 
The prospect of progressively stricter laws over CFCs and 
other ozone depleting substances sparked the continuous inven-
tion of alternatives, including improved methods of using natural 
refrigerants, making the chemicals once displaced by CFCs a 
viable alternative to ozone depleting substances and greenhouse 
gasses.58 Together, the experiences of both phthalates and CFCs 
illustrate how the systematic introduction of progressively 
stricter rules at the global and regional levels spurred the con-
tinuous invention of safer chemicals, averting the serious conse-
quences of inaction and disproving the estimated cost of action. 
chemIcal laws can—BuT noT always do—
pull saFer InvenTIons InTo The markeT
For quite some time I have been confronted with problems 
from the plasticizers in vinyl for aerospace applications and I 
Table 1. Intrinsic properties of various chemical refrigerants. 
Chemical Ozone depleting potential 
(relative to CFC-11)
Global warming potential 
(relative to CO2)
Other hazardous properties
Ammonia* 0 < 1
 
Highly toxic (but odor enables evacuation), 
slightly flammable





Hydrocarbons* 0 ~20 Flammable
*“Natural” refrigerants53
Figure 3. Innovation 
Cycle of Refrigerants. 
Innovation of various 
chemical refriger-
ants over the 20th and 
21st centuries. Dates 
are approximations 
based on major usage 
and expected reduc-
tions under national 
and international 
agreements.52
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have long since come to the conclusion that vinyl should not 
be permitted in any phase of aerospace usage . . . . [S]ubstitute 
polymers for the vinyl are readily available and in many cases 
they have far superior physical properties at a small sacrifice in 
immediate cost.
—­Frederick G. Gross, NASA Materials 
Engineering Branch, April 26, 197159
Innovation hinges on the adoption of an invention. As 
illustrated above, chemical laws can accelerate the invention 
of alternatives to hazardous chemicals. To replace widely used 
hazardous chemicals, inventors created new chemicals and pro-
cesses, developed new uses for existing chemicals, and found 
alternative approaches. The spike in invention to eliminate cer-
tain phthalates shows that environmental laws can be a critical 
element—a driver—in accelerating invention in the chemical 
industry. 
Chemical laws can also pull inventions into the market, 
thereby turning invention into innovation. The above examples 
of CFCs and phthalates illustrate this. Some of the alternatives 
used for certain phthalates and CFCs existed well-before the 
prospect of stricter laws was on the horizon. Until the prospect 
of enacting stricter restrictions on the use of these entrenched 
and hazardous chemicals, companies sidelined these alterna-
tives, with far less opportunity for adoption in the market and 
further development through experience gained from their suc-
cesses and shortcomings. 
Some of the replacements for chemicals of concern, 
however, have been very unsatisfying. History is replete with 
examples of regrettable substitution, where years of concerted 
effort is undertaken to restrict or phase-out an individual chemi-
cal of concern, only to see the chemical replaced with a different 
chemical of concern.60 This unsatisfying transition has under-
mined the confidence of the public and businesses in the ability 
of innovation alone to ensure meaningful progress towards safer 
alternatives. Below, is a cross-section of examples of substitu-
tion, ranging from clearly regrettable substitutes, to the entry of 
alternatives that raise questions, and finally, to more promising 
examples. 
regrettable substitution
Over the last several decades, demand for chemical flame-
retardants has accelerated. Production increased from just over 
500 million pounds in 1983, to 3.4 billion pounds in 2009, and 
projections expect it to jump another 30% to 4.4 billion pounds 
by 2014.61 The transition away from toxic flame-retardants pro-
vides one example for regrettable substitution. 
Polychlorinated biphenyls (“PCBs”) and polybrominated 
biphenyls (“PBBs”) were widely used as flame-retardants until 
the 1970s, when health and environmental concerns began to sur-
face.62 When PCBs and PBBs were banned as flame-retardants, 
polybrominated diphenyl ethers (“PBDEs”) took their place in 
the market as flame-retardants. Under U.S. and European laws at 
the time, PBDEs were considered “existing” chemicals, mean-
ing no evidence of safety was required for these chemicals to 
remain on the market when industrial chemical laws were passed 
in the 1970s in the United States and Europe.63 Production and 
use increased rapidly for PBDEs over the next several decades 
as new markets for them emerged, or were created, including 
furniture foam, electronics, textiles, and baby products.64
Overwhelming evidence has emerged about the hazards of 
PBDEs, including their endocrine disrupting properties.65 Not 
only do these chemicals exhibit toxicity at both high and low-
doses, but they persist in the environment rather than breaking 
down into safer constituents, accumulate in living organisms, 
and travel long distances by wind, water, animals in which 
they have accumulated, and products traded internationally. As 
evidence of the dangers of PBDEs grew overwhelming, many 
countries around the world began to phase out certain PBDEs, 
creating the possibility for the entry of safer alternatives.66 In 
other countries, manufacturers of PBDEs agreed to voluntarily 
discontinue the production and sale of these chemicals. The 
Stockholm Convention, a global treaty that applies to some 
of the world’s most hazardous chemicals, banned two types of 
PBDEs in 2009.67 PBDEs are one example of regrettable substi-
tution among a cluster of toxic flame-retardants.
Unfortunately, one of the replacements for certain PBDEs 
is yet another episode of regrettable substitution. The U.S. 
Environmental Protection Agency (“EPA”) approved Firemaster 
550™, a mixture of several chemicals, in 2003 under the U.S. 
Toxic Substances Control Act’s (“TSCA”) provisions for the 
approval of new chemicals.68 Because of the limited power for 
regulators to demand sufficient proof of safety before compa-
nies produce a new chemical for use, the EPA could only use 
the scant information provided by the manufacturer, Chemtura, 
and computer models to predict the chemical mixture’s toxicity. 
According to a U.S. EPA official, “[w]e didn’t think [Firemaster 
550™] would bioaccumulate, but it turns out that prediction 
isn’t borne out by reality.”69 
Regulators in the United States approved Firemaster 550™ 
for use, even though it had suspicions, including the structural 
similarity of a chemical ingredient of Firemaster 550™ to 
DEHP, a phthalate restricted from certain uses due to evidence 
that it is a reproductive toxin. U.S. authorities asked Chemtura 
to provide additional studies. Chemtura provided two of its own 
studies, five years later, which showed adverse effects at high-
doses, such as skeletal malformations and low-birth weight. But 
the company argued that these results were inconclusive.70
Although advertised as a “green” replacement to PBDEs,71 
evidence continues to emerge that one or more ingredients of 
Firemaster 550™ are released from products containing the mix-
ture, could be toxic, accumulate in wildlife, travel long-distances 
through the environment, and may have adverse effects at low 
doses.72 Like PBDEs and structurally similar phthalates, recent 
studies indicate that some of Firemaster 550™'s ingredients 
have endocrine disrupting properties.73 Yet Firemaster 550™ 
remains in use. 
more Promising examPles of substitution
Chemists have discovered ways to design chemicals to 
make them inherently safer. An older example is the ability to 
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design chemicals so that they do not persist as long in the envi-
ronment.74 One such technique is the use of secondary nitrogen 
atoms instead of tertiary nitrogen atoms to enhance biodegrad-
ability, as demonstrated with the use of ethylenediamine-N,N’-
disuccinic acid (“EDDS”) instead of ethylenediaminetetraacetic 
acid (EDTA) as a complexing agent. Complexing agents like 
EDTA can be used to improve cleaning efficiency by sequester-
ing metals in water-based solutions, but they also raise concerns 
about their ability to mobilize toxic metals in the environment.75 
Some countries and regions have phased out EDTA for certain 
applications.76 EDDS is far more biodegradable than EDTA and 
also performs better as a complexing agent in some applications. 
With the increasing stringency of measures on the use of 
certain phthalates, including the scheduled phase out of four 
phthalates (DEHP, DBP, BBP, and DIBP) from certain products 
in the European Union by February 21, 2015, alternatives are 
increasingly being demonstrated as viable and adopted.77 While 
some phthalate-based alternatives raise questions, other alterna-
tives to phthalates show more promise.
For example, experiments with different types of raw mate-
rials as feedstocks have resulted in a castor-oil-based alternative 
to phthalate plasticizers for PVC (Soft-n-Safe™). It has been 
approved for use in food contact surfaces, vinyl flooring and 
wallpaper, toys, medical devices, inks, textile dyes, and other 
applications.78 This direct substitute does not exhibit many 
of the intrinsic hazards of phthalates and other plasticizers. 
Notably, and unlike the phthalates they replace, studies show no 
evidence of endocrine disruption or other adverse effects for this 
alternative.79 
In the effort to remove phthalates from products, other com-
panies have removed a principle reason phthalates are used in the 
first place—PVC. For example, office products retailer Staples® 
removed PVC from its packaging materials.80 Downstream 
users are also removing phthalates by removing the PVC. Of 
particular concern is the use of phthalate-containing PVC for 
blood bags and other infusion/transfusion sets, which can sub-
ject very young children to hazardous levels of the phthalate 
DEHP during critical windows of development. As a result of 
recent measures for particular phthalates, medical suppliers that 
provide phthalate-free alternatives to PVC medical devices are 
experiencing a boom in both demand and growth.81 
Innovators have also found safer alternatives to treating 
furniture foam with toxic chemicals to prevent furniture fires. 
For example, specially designed upholstery can resist smolder-
ing cigarettes, preventing underlying foam from igniting. In 
addition, researchers developed non-toxic fire-resistant barriers, 
adopted by mattress manufacturers. Both of these alternatives 
are far more effective at slowing fire than adding flame retardants 
to foam, which in fact does not slow the fire by any significant 
degree according to several tests by government agencies and 
independent laboratories.82
The above examples illustrate how invention has been 
sparked by laws to reduce or eliminate hazardous chemicals. 
First-movers may have a considerable advantage over competi-
tors as demand and requirements for safer products increase.
requIremenTs For sTrIcTer chemIcals laws 
Legal controls cleared the way for the adoption of alterna-
tives, pulling newly developed or pre-existing solutions to occupy 
the space vacated by certain hazardous chemicals. In order to 
increase the likelihood that safer alternatives will be pulled into 
the market, the law needs to clearly identify hazardous properties 
that are not acceptable in society and require their substitution 
with safer alternatives (including non-chemical alternatives) in 
a systematic way. For example, the EU’s REACH authorization 
procedure gives a clear signal to industry that chemicals that are 
carcinogens, mutagens, or toxic to reproduction, and those that 
exhibit persistence and bioaccumulation, need to be substituted 
with safer alternatives.83 This provides clear direction to chemi-
cal manufacturers and downstream users of chemicals that they 
must innovate away from chemicals with these properties. 
The availability of information about chemical hazards and 
the prospect of regulatory action accelerate research towards 
safer solutions, whether it is through the invention of new chem-
icals, new applications of existing chemicals, new materials, or 
new processes.84 But more critically, stricter requirements that 
chemical manufacturers generate information about intrinsic 
hazards and exposures can drive innovation in a safer direction. 
Without information about the full scope of intrinsic hazards of 
all chemicals, downstream businesses are highly vulnerable to 
investing in the substitution of one hazardous chemical with a 
different hazardous chemical. Some might say they risk jumping 
from the frying pan into the fire. 
The surge in the invention of alternatives to phthalates 
began the same time as European laws limited the use of six 
widely used phthalates in toys and other children’s products, 
a small percentage of global phthalate use.85 To some degree, 
both the number of phthalates and the number of products within 
the scope of laws around the world are increasing and stand to 
increase further as the deadline for authorization of uses for 
certain phthalates approaches in the EU.86 This trend towards 
stricter laws over the use of phthalates spurred the invention of 
phthalate alternatives beyond the miniscule share of the market 
occupied by toys and children’s products.87
The ability of chemical laws to pull inventions into the 
market is a crucial aspect of the potential power of chemicals 
policies to spur innovation toward safer alternatives. Businesses 
may argue that environmental laws follow the invention of alter-
natives to hazardous chemicals and thus are not a driver of inno-
vation. But it is the prospect of stricter measures that often drives 
the research and development of new ideas and later enables the 
entry of these ideas into the market.88 The acceleration in the 
number of non-phthalate and phthalate-free patents illustrates 
how the prospect of progressively stricter rules against the use 
of hazardous chemicals can incentivize, or push, companies to 
develop alternatives (see Figures 1 and 2). 
Part of this ability comes from the power of the law to enable 
new ideas, safer alternatives in this case, to overcome barriers 
to entry. Even if a safer alternative to a chemical of concern is 
invented and available for adoption, there are many factors that 
present barriers to its entry into the market. 
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One factor is the substantial economies of scale for exist-
ing chemicals.89 These economies of scale result not only from 
the economies inherent in higher production volumes but also 
from long periods in which innovations could occur around their 
production and use, with resulting increases in efficiencies and 
demand.90 The discovery of new uses, increasing production 
volumes and the development of more efficient processes for 
chemical synthesis enable existing chemicals to become more 
and more entrenched in products and processes. 
Second, the continued externalization of costs by the chemi-
cal industry makes it difficult for safer alternatives to compete 
on a level playing field.91 Externalities are costs or benefits 
arising from an economic activity that affect somebody other 
than the people engaged in the economic activity and are not 
reflected fully in prices.92 Recent analyses by the United Nations 
Environment Programme (“UNEP”) highlight the cost of inac-
tion for the sound management of chemicals on human health 
and the environment, with large burdens falling on individuals 
and government budgets. These reports conclude that, “the vast 
majority of human health costs of chemical production, con-
sumption and disposal are not borne by chemical producers, or 
shared down the value-chain. Uncompensated harm to human 
health and the environment are market failures that need to be 
corrected.”93
A third factor is an inability of businesses, consumers, and 
regulators to access information about the hazards of chemicals 
and products containing hazardous chemicals.94 The vast major-
ity of chemicals lack adequate information about their adverse 
effects, such as their potential for endocrine disruption.95 This is 
due in large part to chemical policies adopted around the world 
in the 1970s that presumed the safety of nearly all chemicals 
in commerce. Policies have changed in Europe and elsewhere 
to require basic information on the most widely used industrial 
chemicals. For example, 72% of businesses surveyed responded 
that REACH had led to increased access to information about 
chemicals.96 Small firms benefited more than larger firms in 
terms of conception of products resulting from increased infor-
mation enabled by REACH, in particular information about 
hazardous substances communicated along the supply chain 
(through Safety Data Sheets).97 
Despite information generated to date under REACH, the 
ongoing dearth of information remains a concern. As informa-
tion is generated in the coming years for “existing” lower pro-
duction volume chemicals, the benefits of information generated 
by REACH for innovation is likely to grow.98
Stricter chemical laws can help to pull inventions into the 
market. But, safer chemicals will continue to face an uphill bat-
tle in displacing hazardous chemicals as long as: (1) economies 
of scale are not addressed; (2) the costs of hazardous chemicals 
remain externalized to the public; and (3) information asym-
metries continue to exist. Effective chemical laws can and must 
address these factors, enabling the adoption of safer chemicals 
and thus innovation towards safer products and processes.
sTrIcTer chemIcals laws dIrecT resources 
Toward InnovaTIon and The developmenT oF 
saFer alTernaTIves
It is argued that strict regulation entails unnecessary costs 
to the regulated industry and hampers the introduction of certain 
inventions. Ideally, inventions not allowed onto the market would 
be those that are dangerous to human health or the environment 
or are otherwise undesirable. Achieving the appropriate balance 
between measures to protect human health and the environment 
on the one hand, and the freedom to experiment and develop 
better solutions to problems on the other, is something most 
stakeholders can agree upon, although where this balance lies is 
at the center of many contentious debates. 
Responding to a survey commissioned by the European 
Commission about the impacts of EU REACH on innovation, 
some businesses claimed that there has been a significant redi-
rection of skilled personnel from R&D and innovation-related 
activities to compliance work as a result of the implementation 
of the regulation.99 But since the 1970s, scholars have questioned 
the notion that stricter laws direct resources away from R&D and 
innovation-related activities.100 Scholars conclude from these 
studies that, “innovation is indeed being changed by regulation, 
but that there is a redirection of innovative efforts into more 
socially approved areas, rather than an absolute decline.”101 
Overall, responses tended to reflect the European Commission’s 
Economic Impact Analysis: negative effects of having to meet 
compliance requirements could dominate in the short term, with 
significant positive impacts on innovation expected in the longer 
term.102
Other findings of the independent survey suggest that, in 
fact, more resources have been directed towards innovation as 
a result of the EU’s REACH Regulation. For example, regard-
ing the impact of REACH on innovation, nearly half of survey 
respondents report that as a result there has been an increase in 
expenditure on research and development (“R&D”) and related 
innovative activities.103 Two reasons were suggested for this 
increase: the inability to stop innovation programs that were of 
strategic importance to the firms in question, and—most signifi-
cantly—the creation of new opportunities due to the coming into 
force of the REACH Regulation.104
Of concern during debates over the possible impact of 
REACH’s requirements was the impact of the Regulation on 
innovation by small and medium-sized enterprises (“SMEs”). 
Notably, small, medium and large businesses were all among 
those reporting an increase in expenditure on R&D in response 
to the stricter requirements of REACH.105 
In short, regarding the overall effect of mechanisms within 
REACH on the willingness and determination of businesses to 
innovate, the REACH Innovation Report concludes that despite 
having to bear the additional costs of REACH, firms have con-
tinued to innovate and are keen to continue to do so.106 
Moreover, some of the responses illuminate the potential 
for the creation of new, highly specialized jobs. As informa-
tion comes due for submission for an increasing number 
of chemicals under REACH, it is believed that demand for 
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human resources with technical and regulatory expertise will 
increase.107 Universities responded to this new demand by 
developing chemistry curricula with a specialization in REACH. 
The authors of the REACH innovation report conclude that as a 
result of REACH, “it is envisaged that over time the number and 
quality . . . of skilled human resources to industry will increase 
and be supportive of innovative activity.”108
The above patent findings also support the conclusion that 
stricter rules for chemical safety can drive greater resources 
towards invention and innovation. The above-mentioned accel-
eration in the number of patents claiming phthalate-alternative 
or phthalate-free invention is one indication of an increase in 
resources towards invention and innovation. Indeed, the most 
active companies are some of the biggest manufacturers of 
phthalates—Exxon Mobil, Dow, and Eastman Kodak/Eastman 
Chemical (see Figure 2). In addition to these three large chemical 
manufacturers, the study found that eighty-five other companies 
obtained at least one patent for a “non-phthalate” or “phthalate-
free” invention. 
The most common phthalate measure restricts six phthalates 
above a certain concentration in toys and children’s products. 
However, the study found that approximately 95% of the patents 
identified were not limited to infant and children’s products. 
Moreover, inventions were disclosed for the use of phthalates in 
a range of products, much broader than the limited market seg-
ment singled out under the law.109 These patent filings suggest 
that as the likelihood of stricter rules over existing chemicals 
of concern increased, resources were devoted to innovation to 
maintain or even capture market share. 
Thus, while some may argue that stricter rules for ensur-
ing chemical safety may direct resources away from innovation, 
recent experiences suggest that the desire to maintain market 
share by industry is sufficient to direct resources towards the 
innovation of safer alternatives and the development of new, 
innovation-friendly skills. 
conclusIon
Consumers, downstream users, and investors are increas-
ingly demanding products free of hazardous chemicals through-
out their life-cycle. In addition to customer demand, businesses 
increasingly recognize that the transition away from hazardous 
chemicals is often accompanied by the emergence of a com-
petitive advantage and market opportunities. Effective chemical 
policies must be in place to reward businesses that develop safer 
approaches by enabling their ideas to replace those that are less 
safe.
The question is then how to spur the innovation of approaches 
that stand to provide the most improvement to people, wildlife, 
and the environment from the status quo of chemicals. And then, 
for those inventions that are indeed a safer alternative, how to 
effectively overcome barriers to entry so that these safer alterna-
tives can displace incumbent hazardous chemicals and produc-
tion processes in the marketplace. 
The findings of this study suggest that progressively stricter 
laws, with a gradual phase-out of chemicals with certain intrin-
sic hazards, spur the innovation of alternatives, with the poten-
tial to pull safer alternatives into the market, enabling them to 
overcome barriers to entry. This enables innovators that seek 
comparative advantages to continuously innovate towards the 
safest alternative for various uses and allows predictability for 
industry and investors.  
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